Ultimovacs AS Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.11.23	Ultimovacs ASA: Invitation to third quarter 2023 results webcast presentation (GlobeNewswire)
02.11.23	Ultimovacs Announces Completion of Patient Enrollment in Supplementary Study to INITIUM, UV1 Phase II Trial in Malignant Melanoma (GlobeNewswire)
31.10.23	Ultimovacs Announces Protocol Amendment in UV1 Phase II Study INITIUM in Malignant Melanoma, Enabling Data Readout in First Half of 2024 (GlobeNewswire)
25.10.23	Ultimovacs Announces Webcast to Elaborate on the Results from Randomized UV1 Phase II NIPU Trial in Malignant Mesothelioma (GlobeNewswire)
23.10.23	Ultimovacs Provides Complete Phase II NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients with Malignant Mesothelioma Receiving UV1 (GlobeNewswire)
17.10.23	Ultimovacs Announces NIPU Results Presented at ESMO 2023: Significant and Clinically Meaningful Improvement in Overall Survival for Patients Receiving UV1 Cancer Vaccine in Phase II NIPU Trial in Mali (GlobeNewswire)
12.10.23	Ultimovacs Provides 4-Year Update from Phase I Study in Malignant Melanoma: Demonstrating Sustained Long-Term Overall Survival in Patients Treated with UV1 Cancer Vaccine (GlobeNewswire)
09.10.23	Ultimovacs Receives FDA Orphan Drug Designation for the UV1 Cancer Vaccine for Treatment of Mesothelioma (GlobeNewswire)
27.09.23	Ultimovacs Announces that the Results from UV1 Phase II Clinical Trial NIPU in Malignant Mesothelioma will be Presented at the ESMO Congress 2023 (GlobeNewswire)
22.08.23	Ultimovacs ASA Reports Second Quarter 2023 Financial Results and Provides General Business Update (GlobeNewswire)
16.08.23	Ultimovacs ASA: Invitation to second quarter 2023 results webcast presentation (GlobeNewswire)
03.08.23	Ultimovacs Announces Completed Enrollment in FOCUS Phase II Clinical Trial of UV1 in Head and Neck Cancer Patients (GlobeNewswire)
28.06.23	Ultimovacs Announces Publication in Clinical Cancer Research of the UV1-103 Phase I Malignant Melanoma Trial Results (GlobeNewswire)
22.06.23	Ultimovacs’ Chief Scientific Officer Gustav Gaudernack Receives Norwegian Tech Award’s Honorary Prize as an Outstanding Pioneer Against Cancer (GlobeNewswire)
19.06.23	Ultimovacs Provides 3-Year Update from Phase I Study in Malignant Melanoma: Results Confirm Strong Overall Survival in Patients Treated with UV1 Cancer Vaccine (GlobeNewswire)
08.06.23	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
08.06.23	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
07.06.23	Ultimovacs provides update on Phase II NIPU trial evaluating UV1 in second-line patients with malignant pleural mesothelioma (GlobeNewswire)
10.05.23	Ultimovacs ASA Reports First Quarter 2023 Financial Results and Provides General Business Update (GlobeNewswire)
03.05.23	Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation (GlobeNewswire)
25.04.23	Ultimovacs provides updated guidance on timeline for readout of INITIUM Phase II clinical trial of UV1 in malignant melanoma (GlobeNewswire)
21.04.23	Ultimovacs ASA - Share Option Program (GlobeNewswire)
20.04.23	Ultimovacs ASA – Annual General Meeting held on 20 April 2023 (GlobeNewswire)
14.04.23	Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting (GlobeNewswire)
13.04.23	Ultimovacs Receives Intention to Grant Notice on European Patent on UV1 Cancer Vaccine-Checkpoint Inhibitor Combinations (GlobeNewswire)
24.03.23	Ultimovacs ASA: Notice of Annual General Meeting on 20 April 2023 (GlobeNewswire)
24.03.23	Ultimovacs ASA: Annual Report 2022 (GlobeNewswire)
27.02.23	Ultimovacs to Present at Cowen Healthcare Conference (GlobeNewswire)
16.02.23	Ultimovacs ASA Reports Fourth Quarter 2022 Financial Results and Provides General Business Update (GlobeNewswire)
18.10.22	Ultimovacs Announces New UV1 Data Showing Enhanced Efficacy Including in Hard-to-Treat Cancer Patients, Supporting Broad Utility (GlobeNewswire)
21.09.22	Ultimovacs Announces Plenary Oral Presentation of Phase I Melanoma Trial Results at the 19th International Congress of the Society for Melanoma Research (SMR) (GlobeNewswire)
12.09.22	Ultimovacs Announces Publication of Phase I Melanoma Trial Data in Journal of Translational Medicine (GlobeNewswire)
09.09.22	Ultimovacs ASA: New share capital registered (GlobeNewswire)
05.09.22	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
05.09.22	Ultimovacs ASA: Share capital increase related to exercise of options (GlobeNewswire)
22.08.22	Ultimovacs Strengthens IP Portfolio with the United States Patent and Trademark Office (USPTO) Notice of Allowance on UV1 Method Patent (GlobeNewswire)
19.08.22	Ultimovacs ASA Reports Second Quarter 2022 Financial Results and Provides General Business Update (GlobeNewswire)
18.08.22	Ultimovacs Expands High Dose Cohort Size in TENDU Phase I Prostate Cancer Trial after Safety Review (GlobeNewswire)
12.08.22	Ultimovacs ASA: Invitation to second quarter 2022 results webcast presentation (GlobeNewswire)
30.06.22	Ultimovacs ASA: Mandatory notification of trade by primary insider (GlobeNewswire)
30.06.22	Ultimovacs Completes Patient Recruitment in INITIUM Phase II Trial of UV1 in Malignant Melanoma (GlobeNewswire)
20.06.22	Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial (GlobeNewswire)
25.05.22	Ultimovacs’ Clinical Data in Journal for ImmunoTherapy of Cancer Show Long-term Dynamic T Cell Responses with UV1 and Checkpoint Inhibitor Synergy (GlobeNewswire)
12.05.22	Ultimovacs ASA: First quarter 2022 result presentation (GlobeNewswire)
10.05.22	Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting (GlobeNewswire)
05.05.22	Ultimovacs ASA: Invitation to first quarter 2022 results webcast presentation (GlobeNewswire)
22.04.22	Ultimovacs Receives Notice of Allowance on US Patent on Vaccine-Checkpoint Inhibitor Combinations (GlobeNewswire)
21.04.22	Ultimovacs ASA - Share Option Program (GlobeNewswire)
21.04.22	Ultimovacs ASA – Annual General Meeting held on 21 April 2022 (GlobeNewswire)
08.04.22	Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Ultimovacs AS Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten